Clinical trials · source year
234 selected, source-linked clinical trial records dated 2026. This is selective source coverage, not a complete timeline.
234 selected records.
28 connected profiles.
234 distinct public records.
Cited chronology
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07218354 at 2026-08-13T05:54:14.857Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT06632444 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Petrelintide
PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT05663515 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Cagrilintide
PeptideScanner retained ClinicalTrials.gov record NCT07745504 at 2026-08-13T05:52:27.004Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was cagrilintide.
Source: ClinicalTrials.gov ↗
Cagrilintide
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Pemvidutide
PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Retatrutide
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
Source: ClinicalTrials.gov ↗
Retatrutide
PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT05796388 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07559500 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07732426 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06072963 at 2026-08-10T18:10:03.864Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT06388642 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT07496463 at 2026-08-10T18:10:04.219Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Plecanatide
PeptideScanner retained ClinicalTrials.gov record NCT07723924 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was plecanatide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT07587775 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT03796884 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT06164795 at 2026-08-10T18:10:03.919Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Survodutide
ClinicalTrials.gov lists an active, not recruiting Survodutide study sponsored by Boehringer Ingelheim.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06975111 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07715929 at 2026-08-10T18:10:04.226Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT07718126 at 2026-08-10T18:10:03.957Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.
Source: ClinicalTrials.gov ↗
Mazdutide
ClinicalTrials.gov lists a Mazdutide study that is not yet recruiting sponsored by West China Hospital.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07707778 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Retatrutide
ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07602699 at 2026-08-10T18:10:03.953Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Cagrilintide
ClinicalTrials.gov lists a recruiting Cagrilintide study sponsored by Novo Nordisk A/S.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06814938 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT06817356 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT06596135 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Elamipretide
ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05498272 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02319837 at 2026-08-10T18:10:03.933Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07693608 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05569772 at 2026-08-10T18:10:03.935Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Petrelintide
ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.
Source: ClinicalTrials.gov ↗
Petrelintide
PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05371496 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07671248 at 2026-07-30T16:38:53.229Z. Its registry update date was 2026-07-01, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Cagrilintide
PeptideScanner retained ClinicalTrials.gov record NCT07220642 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was cagrilintide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04777409 at 2026-07-30T16:19:03.047Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07592546 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07505303 at 2026-07-30T16:19:03.067Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07668414 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03070886 at 2026-07-30T16:19:03.056Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT07158021 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04423211 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT07657676 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT07650240 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT07654062 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05726227 at 2026-07-30T16:19:03.202Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT07027124 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05605964 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00329043 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07382024 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06864026 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06305598 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07282769 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07462663 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT04467983 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-08, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06976853 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07218445 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07630454 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05424003 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07228741 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07627074 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07204249 at 2026-07-30T16:19:03.057Z. Its registry update date was 2026-06-03, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06571383 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07610174 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05774756 at 2026-07-30T16:19:36.905Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06485089 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT07469800 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04126070 at 2026-07-30T16:19:36.912Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05333003 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07605247 at 2026-07-30T16:19:36.902Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02860923 at 2026-07-30T16:19:36.924Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04469855 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01293292 at 2026-07-30T16:19:36.921Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Pemvidutide
PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06041217 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Pemvidutide
ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00544830 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Cagrilintide
PeptideScanner retained ClinicalTrials.gov record NCT07557953 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was cagrilintide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT05652205 at 2026-07-30T16:19:36.913Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT05151484 at 2026-07-30T16:19:36.911Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07523633 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT03770338 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01155232 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05586802 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07059377 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06734273 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07298915 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04019197 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07443956 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07554638 at 2026-07-30T16:19:36.907Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04194554 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT06176365 at 2026-07-30T16:20:49.317Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT06309992 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-30, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04174755 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT05500586 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT03841058 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07065552 at 2026-07-30T16:20:49.313Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06283667 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT06124807 at 2026-07-30T16:20:49.321Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05746039 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT06424106 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06657209 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT05482789 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT06558188 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-17, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06811324 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02772588 at 2026-07-30T16:20:49.312Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02960022 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06751589 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Petrelintide
PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06604624 at 2026-07-30T16:20:49.309Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT03119584 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT06264609 at 2026-07-30T16:20:49.326Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06734130 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT07126262 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT02817659 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-30, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Ziconotide
PeptideScanner retained ClinicalTrials.gov record NCT07499882 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-30, and PeptideScanner's reviewed identity mapping was ziconotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05933499 at 2026-07-30T16:22:22.327Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06118203 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07220473 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Petrelintide
PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.
Source: ClinicalTrials.gov ↗
TB-500
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
Source: ClinicalTrials.gov ↗
Pemvidutide
PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07227948 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT04219007 at 2026-07-30T16:22:22.347Z. Its registry update date was 2026-03-18, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06934655 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06989177 at 2026-07-30T16:22:22.331Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06989203 at 2026-07-30T16:22:22.329Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT02724228 at 2026-07-30T16:22:22.336Z. Its registry update date was 2026-03-13, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT04554940 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-13, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07468552 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT06252493 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07213466 at 2026-07-30T16:22:22.332Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT05845749 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT07460908 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06330805 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-09, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00936390 at 2026-07-30T16:22:22.345Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05700903 at 2026-07-30T16:22:22.343Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06027567 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06759701 at 2026-07-30T16:23:45.658Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07095517 at 2026-07-30T16:23:45.642Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
BPC-157
ClinicalTrials.gov lists a recruiting BPC-157 study sponsored by Hudson Biotech.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01786265 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07423247 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05320406 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06517212 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-07-30T16:23:45.672Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06939088 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT03879694 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03902951 at 2026-07-30T16:23:45.660Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04455750 at 2026-07-30T16:23:45.647Z. Its registry update date was 2026-02-05, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT07366710 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-02, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06914102 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06914154 at 2026-07-30T16:25:18.014Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04251156 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07364175 at 2026-07-30T16:25:18.007Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04734730 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07373834 at 2026-07-30T16:25:18.006Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06445075 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05788965 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07242534 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-20, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06852391 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-14, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06042153 at 2026-07-30T16:25:18.002Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06802081 at 2026-07-30T16:25:18.015Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT05866029 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗